David Speicher, MD, is a pediatric critical care physician in the Division of Pediatric Pharmacology and Critical Care at University Hospitals Rainbow Babies & Children's Hospital. He is Assistant Professor, Pediatrics, Case Western Reserve University School of Medicine.
Dr. Speicher is board certified in pediatrics and pediatric critical care and is certified in pediatric advanced life support and advanced cardiovascular life support. His special interests are pediatric extra-corporeal membrane oxygenation and resuscitation. He was named to the medical staff at UH Rainbow Babies & Children's Hospital in 2010.
Dr. Speicher earned a bachelor’s degree in biology from Muhlenberg College, Allentown, Pa., and a doctorate in medicine from Drexel University College of Medicine, Philadelphia, Pa. He served his residency in pediatrics at A.I. DuPont Hospital for Children, Wilmington, Del., and a fellowship in pediatric critical care at UH Rainbow Babies & Children's Hospital.
Dr. Speicher’s research interests include pharmoacokinetcs and bacterial infections in children. Since 2011 he has been principal Investigator and co-investigator on numerous clinical trials related to the treatment of bacterial infections such as pneumonia, clostridium dificile and urinary tract infections in infants and children.
He is a member of the American Academy of Pediatrics and Society of Critical Care Medicine.
Bacterial infections in infants and children
- Pediatric ECMO
UH Rainbow Babies and Children's Hospital
11100 Euclid Ave
Cleveland OH, 44106
Patient Satisfaction Reviews
0 out of 5
- Pediatric Critical Care Medicine - American Board of Pediatrics
- Pediatrics - American Board of Pediatrics
Fellowship | Pediatric Critical Care Medicine
Pediatric Critical Care Medicine - Uh Case Medical Center (2007 - 2010)
Residency | Pediatrics
Pediatrics - Alfred I Dupont Hospital For Children (2004 - 2007)
Drexel University College Of Medicine (2004)
Muhlenberg College (2000)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, David Speicher did not disclose any Outside Relationships with Industry.